FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897833364> ?p ?o ?g. }

• W2897833364 endingPage "278" @default.
• W2897833364 startingPage "265" @default.
• W2897833364 abstract "Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial) Ganna D Radchenko, Liliya O Mushtenko, Yuriy M Sirenko State Institute “National Scientific Center “Institute of Cardiology named after acad.M.Strazhesko” of Ukrainian National Academy of Medical Science, Kyiv, Ukraine Background: The EPHES trial (Evaluation of influence of fixed dose combination Perindopril/amlodipine on target organ damage in patients with arterial HypErtension with or without iSchemic heart disease) compared the dynamics of target organ damage (TOD) in hypertensive patients with and without ischemic heart disease (IHD) treated with the fixed-dose combination (FDC) perindopril + amlodipine. Methods: The analysis included 60 hypertensive patients (aged >30 years): 30 without IHD and 30 with IHD. At randomization, FDC was administered at a daily baseline dose of 5/5 mg with uptitration to 10/10 mg every two weeks. If target blood pressure (BP<140/90 mmHg) was not achieved after six weeks, indapamide 1.5 mg was added to the regimen. All patients underwent body mass index measurements, office and ambulatory BP measurements, pulse wave velocity (PWVe) and central systolic BP evaluation, augmentation index adjusted to heart rate 75 (Aix@75) evaluation, biochemical analysis, ECG, echocardiography with Doppler, ankle-brachial index measurement, and intima-media thickness measurement. The follow-up period was 12 months. Results: Therapy based on FDC perindopril/amlodipine was effective in lowering BP (office, ambulatory, central) in both groups. We noted significant decrease in Aix@75 with the therapy in both groups, but ΔAix@75 was lesser in the group with IHD than the group without IHD. FDC provided significant improvement in PWVe and left ventricular diastolic function, and decrease in albuminuria, left ventricular hypertrophy (LVH), and left atrium size. ΔPWVe was significantly (P<0.005) less in patients without IHD than those with IHD (2.5±0.2 vs 4.4±0.5 m/s, respectively). In spite of almost equal LVH regression, the positive dynamics of ΔE/A and ΔE/E´ were more in patients with IHD than those without IHD (64.4% and 54.1% vs 39.8 and 23.2%, respectively; P<0.05 for both comparisons). Adverse reactions were in 2 (6.5%) patients without IHD and 3 (10%) with IHD (P=NS). In the group with IHD, we noted significant decrease in angina episode rate – from 2.5±0.4 to 1.2±0.2 (P<0.01) per week. Conclusion: Thus, treatment based on FDC was effective in decreasing BP and TOD regression in both patients with and without IHD. However, the dynamics of changes in TOD were different between the two groups, which should be taken into consideration during management of patients with and without IHD. Keywords: arterial hypertension, ischemic heart disease, target organ damage regression, fixed-dose combination, prospective observation, perindopril, amlodipine" @default.
• W2897833364 created "2018-10-26" @default.
• W2897833364 creator A5078856187 @default.
• W2897833364 creator A5043100131 @default.
• W2897833364 creator A5056310074 @default.
• W2897833364 date "2018-10-01" @default.
• W2897833364 modified "2023-10-12" @default.
• W2897833364 title "Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial)" @default.
• W2897833364 cites W1424022164 @default.
• W2897833364 cites W1965106101 @default.
• W2897833364 cites W1981976068 @default.
• W2897833364 cites W1982146830 @default.
• W2897833364 cites W1985649602 @default.
• W2897833364 cites W2007158005 @default.
• W2897833364 cites W2015124409 @default.
• W2897833364 cites W2016907908 @default.
• W2897833364 cites W2017390074 @default.
• W2897833364 cites W2026808703 @default.
• W2897833364 cites W2026862331 @default.
• W2897833364 cites W2030557186 @default.
• W2897833364 cites W2030643305 @default.
• W2897833364 cites W2032461751 @default.
• W2897833364 cites W2046993887 @default.
• W2897833364 cites W2048813770 @default.
• W2897833364 cites W2052652237 @default.
• W2897833364 cites W2064016507 @default.
• W2897833364 cites W2069473110 @default.
• W2897833364 cites W2079429760 @default.
• W2897833364 cites W2080243544 @default.
• W2897833364 cites W2080422776 @default.
• W2897833364 cites W2081861176 @default.
• W2897833364 cites W2085243581 @default.
• W2897833364 cites W2096076189 @default.
• W2897833364 cites W2101063703 @default.
• W2897833364 cites W2104577169 @default.
• W2897833364 cites W2108807575 @default.
• W2897833364 cites W2109232495 @default.
• W2897833364 cites W2112650958 @default.
• W2897833364 cites W2116224448 @default.
• W2897833364 cites W2124510586 @default.
• W2897833364 cites W2125062701 @default.
• W2897833364 cites W2125440793 @default.
• W2897833364 cites W2126467846 @default.
• W2897833364 cites W2127250150 @default.
• W2897833364 cites W2127606189 @default.
• W2897833364 cites W2129837832 @default.
• W2897833364 cites W2133012200 @default.
• W2897833364 cites W2133398064 @default.
• W2897833364 cites W2139168645 @default.
• W2897833364 cites W2139968474 @default.
• W2897833364 cites W2142170772 @default.
• W2897833364 cites W2144120465 @default.
• W2897833364 cites W2144528818 @default.
• W2897833364 cites W2148183789 @default.
• W2897833364 cites W2151273903 @default.
• W2897833364 cites W2155121555 @default.
• W2897833364 cites W2155965977 @default.
• W2897833364 cites W2157562960 @default.
• W2897833364 cites W2157677292 @default.
• W2897833364 cites W2160258470 @default.
• W2897833364 cites W2161902880 @default.
• W2897833364 cites W2166478717 @default.
• W2897833364 cites W2166910397 @default.
• W2897833364 cites W2167377428 @default.
• W2897833364 cites W2167557672 @default.
• W2897833364 cites W2168212535 @default.
• W2897833364 cites W2168777650 @default.
• W2897833364 cites W2170282398 @default.
• W2897833364 cites W2291099602 @default.
• W2897833364 cites W2437822687 @default.
• W2897833364 cites W2607031541 @default.
• W2897833364 cites W46360888 @default.
• W2897833364 doi "https://doi.org/10.2147/vhrm.s163608" @default.
• W2897833364 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6188174" @default.
• W2897833364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30349279" @default.
• W2897833364 hasPublicationYear "2018" @default.
• W2897833364 type Work @default.
• W2897833364 sameAs 2897833364 @default.
• W2897833364 citedByCount "7" @default.
• W2897833364 countsByYear W28978333642019 @default.
• W2897833364 countsByYear W28978333642020 @default.
• W2897833364 countsByYear W28978333642021 @default.
• W2897833364 countsByYear W28978333642022 @default.
• W2897833364 countsByYear W28978333642023 @default.
• W2897833364 crossrefType "journal-article" @default.
• W2897833364 hasAuthorship W2897833364A5043100131 @default.
• W2897833364 hasAuthorship W2897833364A5056310074 @default.
• W2897833364 hasAuthorship W2897833364A5078856187 @default.
• W2897833364 hasBestOaLocation W28978333641 @default.
• W2897833364 hasConcept C126322002 @default.
• W2897833364 hasConcept C164705383 @default.
• W2897833364 hasConcept C2777748223 @default.
• W2897833364 hasConcept C2778319312 @default.
• W2897833364 hasConcept C2779200603 @default.
• W2897833364 hasConcept C2779646130 @default.
• W2897833364 hasConcept C71924100 @default.
• W2897833364 hasConcept C84393581 @default.
• W2897833364 hasConceptScore W2897833364C126322002 @default.

• next